Reaction Details Report a problem with these data
Target
IgG receptor FcRn large subunit p51
Ligand
BDBM50270961
Substrate
n/a
Meas. Tech.
ChEMBL_552584 (CHEMBL956456)
IC50
640±n/a nM
Citation
 Mezo, AR; McDonnell, KA; Castro, A; Fraley, C Structure-activity relationships of a peptide inhibitor of the human FcRn:human IgG interaction. Bioorg Med Chem 16:6394-405 (2008) [PubMed]  Article 
Target
Name:
IgG receptor FcRn large subunit p51
Synonyms:
FCGRN_HUMAN | FCGRT | FCRN
Type:
PROTEIN
Mol. Mass.:
39742.86
Organism:
Homo sapiens (Human)
Description:
ChEMBL_627631
Residue:
365
Sequence:
MGVPRPQPWALGLLLFLLPGSLGAESHLSLLYHLTAVSSPAPGTPAFWVSGWLGPQQYLSYNSLRGEAEPCGAWVWENQVSWYWEKETTDLRIKEKLFLEAFKALGGKGPYTLQGLLGCELGPDNTSVPTAKFALNGEEFMNFDLKQGTWGGDWPEALAISQRWQQQDKAANKELTFLLFSCPHRLREHLERGRGNLEWKEPPSMRLKARPSSPGFSVLTCSAFSFYPPELQLRFLRNGLAAGTGQGDFGPNSDGSFHASSSLTVKSGDEHHYCCIVQHAGLAQPLRVELESPAKSSVLVVGIVIGVLLLTAAAVGGALLWRRMRSGLPAPWISLRGDDTGVLLPTPGEAQDADLKDVNVIPATA
  
Inhibitor
Name:
BDBM50270961
Synonyms:
(2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-{2-[(3R)-3-[(2S)-2-[(2S)-2-{2-[(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-methyl-3-sulfanylbutanamido]-3-hydroxybutanamido]acetamido}-3-(1H-imidazol-5-yl)propanamido]-3-phenylpropanamido]-2-oxoazepan-1-yl]acetamido}-4-methylpentanamido]-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl]formamido}-3-sulfanylpropanoic acid | CHEMBL486090
Type:
Small organic molecule
Emp. Form.:
C72H102N18O16S2
Mol. Mass.:
1539.821
SMILES:
CC(C)C[C@H](NC(=O)CN1CCCC[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](N)CCCN=C(N)N)C(C)(C)S)[C@@H](C)O)C1=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(O)=O |r,wU:102.107,83.86,14.14,62.65,18.26,98.104,wD:4.4,43.45,75.79,29.37,51.61,47.49,(27.04,-22.59,;27.04,-21.07,;28.37,-20.3,;25.72,-20.3,;25.72,-18.76,;24.52,-17.88,;23.29,-18.81,;23.23,-20.35,;21.87,-18.22,;20.65,-19.15,;20.97,-20.66,;19.98,-21.84,;18.43,-21.82,;17.5,-20.59,;17.87,-19.1,;16.69,-18.11,;15.34,-18.84,;15.34,-20.39,;14.05,-17.98,;14.05,-16.42,;15.38,-15.66,;16.71,-16.43,;18.04,-15.66,;18.04,-14.13,;16.7,-13.36,;15.37,-14.13,;12.83,-18.86,;11.48,-18.14,;11.48,-16.6,;10.2,-19,;10.2,-20.55,;11.54,-21.32,;12.99,-20.83,;13.91,-22.07,;13.02,-23.32,;11.55,-22.86,;8.81,-18.12,;7.46,-18.84,;7.46,-20.38,;6.18,-17.98,;4.97,-18.86,;3.61,-18.14,;3.62,-16.6,;2.34,-19,;1.13,-18.12,;-.21,-18.9,;-.19,-20.44,;-1.54,-18.13,;-2.87,-18.92,;-4.23,-18.19,;-4.23,-16.64,;-5.52,-19.06,;-5.52,-20.61,;-4.18,-21.39,;-2.84,-20.62,;-1.5,-21.39,;-1.5,-22.94,;-2.84,-23.71,;-4.18,-22.94,;-6.73,-18.17,;-8.09,-18.89,;-8.09,-20.45,;-9.38,-18.02,;-10.6,-18.92,;-9.38,-16.47,;-8.04,-15.7,;-8.04,-14.16,;-6.71,-13.43,;-6.66,-11.89,;-5.31,-11.15,;-7.98,-11.08,;-1.56,-16.59,;-3.1,-16.6,;-1.56,-15.04,;-.01,-16.58,;2.34,-20.55,;1.01,-21.32,;3.67,-21.32,;19.28,-18.45,;19.31,-16.91,;26.99,-17.91,;26.99,-16.37,;28.34,-18.63,;29.55,-17.74,;29.55,-16.21,;30.62,-15.11,;32.11,-15.5,;33.19,-14.4,;32.77,-12.92,;33.85,-11.82,;31.28,-12.54,;30.21,-13.64,;30.81,-18.61,;30.82,-20.14,;32.17,-17.89,;32.38,-16.37,;33.9,-16.11,;34.62,-17.46,;33.55,-18.57,;33.81,-20.08,;32.64,-21.07,;35.26,-20.61,;36.47,-19.75,;36.47,-18.19,;37.8,-17.43,;37.74,-20.59,;39.09,-19.86,;37.75,-22.13,)|
Structure:
Search PDB for entries with ligand similarity: